By Mill Chart
Last update: Jun 10, 2025
EXELIXIS INC (NASDAQ:EXEL) stands out as an undervalued stock with solid fundamentals, making it a potential candidate for value investors. The company, which focuses on developing oncology treatments, scores well across key financial metrics, including valuation, financial health, profitability, and growth.
Valuation (Score: 8/10)
Financial Health (Score: 9/10)
Profitability (Score: 8/10)
Growth (Score: 8/10)
EXELIXIS combines an attractive valuation with strong fundamentals, making it a rare find in the biotech sector. Its debt-free status, high profitability, and robust growth prospects position it well for long-term investors.
For a deeper dive, review the full fundamental analysis of EXELIXIS.
Our Decent Value Stock Screener provides more undervalued stocks with solid fundamentals.
This is not investment advice. Always conduct your own research before making investment decisions.
NASDAQ:EXEL (7/1/2025, 11:44:04 AM)
43.98
-0.09 (-0.2%)
Find more stocks in the Stock Screener
EXELIXIS (NASDAQ:EXEL) is a strong growth stock with breakout potential, backed by robust earnings, revenue growth, and a healthy technical setup.
EXELIXIS INC (NASDAQ:EXEL) shows strong earnings momentum, expanding margins, and a high technical rating, making it a candidate for growth investors. The stock is consolidating with clear support levels, suggesting a potential breakout opportunity.
EXELIXIS INC (NASDAQ:EXEL) shows strong growth momentum and meets Minervini’s trend criteria, making it a stock to watch for high-growth investors.
Wondering what's happening in Monday's pre-market session? Find an overview in this article.
EXELIXIS INC (NASDAQ:EXEL) meets key growth investing criteria with strong earnings, revenue growth, and profitability, making it a standout for investors following Louis Navellier's strategy.
EXELIXIS INC (NASDAQ:EXEL) offers strong growth, solid profitability, and reasonable valuation, making it a compelling choice for investors seeking affordable growth stocks in the biotech sector.